Kim, Dongsung http://orcid.org/0000-0003-4152-628X
Herdeis, Lorenz http://orcid.org/0000-0001-5867-0216
Rudolph, Dorothea
Zhao, Yulei http://orcid.org/0000-0002-2242-3843
Böttcher, Jark http://orcid.org/0000-0003-2189-5926
Vides, Alberto
Ayala-Santos, Carlos I.
Pourfarjam, Yasin
Cuevas-Navarro, Antonio http://orcid.org/0000-0001-6208-6944
Xue, Jenny Y. http://orcid.org/0000-0003-1192-1836
Mantoulidis, Andreas
Bröker, Joachim
Wunberg, Tobias
Schaaf, Otmar
Popow, Johannes
Wolkerstorfer, Bernhard
Kropatsch, Katrin Gabriele
Qu, Rui
de Stanchina, Elisa
Sang, Ben
Li, Chuanchuan
McConnell, Darryl B. http://orcid.org/0000-0002-2537-3458
Kraut, Norbert http://orcid.org/0000-0003-3941-7105
Lito, Piro http://orcid.org/0000-0003-2196-3503
Article History
Received: 8 September 2022
Accepted: 24 April 2023
First Online: 31 May 2023
Competing interests
: P.L. is listed as an inventor on patents filed by MSKCC on the treatment of KRAS or BRAF mutant cancers (US20200009138A1). P.L. reports grants to his institution from Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim and Virtec Pharmaceuticals. P.L. reports consulting fees from Black Diamond Therapeutics, AmMax, OrbiMed, PAQTx, Repare Therapeutics and Revolution Medicines, travel reimbursement from Boehringer Ingelheim as well as membership of the Scientific Advisory Board of Frontier Medicines (consulting fees and equity). L.H., D.R., J.B., B.W., K.G.K., D.B.M. and N.K. are employed by Boehringer Ingelheim. The remaining authors declare no competing interests.